Peter Donnelly is Director of the Wellcome Trust Centre for Human Genetics and Professor of Statistical Science at the University of Oxford, and a founder and director of Genomics plc, a fast-growing company in the genome analytics space. He has played a leading role in many of the major projects and developments at the interface between genetics, healthcare, and clinical medicine, including the HapMap project, the Wellcome Trust Case Control consortia, and WGS500, one of the studies pioneering whole genome sequencing in clinical medicine.
Session Abstract – PMWC 2018 Silicon Valley
Session Synopsis: AI has the potential to expedite the clinical drug discovery and development process by applying sophisticated algorithms to the analysis and mining of different data sources to predict molecule behavior and suitability as drug targets or therapeutic entities. This session will cover different approaches and AI platforms, and how they will impact the pharmaceutical industry and specifically, the drug discovery and development processes.